In several mouse models of AD, PCS decreased amyloid burden by altering the processing of APP, reducing neuronal hyperexcitability, and attenuating NLRP3 inflammasome activation (Chartampila et al. 2023; Mellott et al. 2017; Wang et al. 2019). The gene discussed is APP; the disease is Alzheimer disease.